AU2020308868A1 - CD3 antigen binding fragments and compositions comprising same - Google Patents

CD3 antigen binding fragments and compositions comprising same Download PDF

Info

Publication number
AU2020308868A1
AU2020308868A1 AU2020308868A AU2020308868A AU2020308868A1 AU 2020308868 A1 AU2020308868 A1 AU 2020308868A1 AU 2020308868 A AU2020308868 A AU 2020308868A AU 2020308868 A AU2020308868 A AU 2020308868A AU 2020308868 A1 AU2020308868 A1 AU 2020308868A1
Authority
AU
Australia
Prior art keywords
seq
amino acid
acid sequence
receptor
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2020308868A
Other languages
English (en)
Inventor
André FRENZEL
Philipp KUHN
Darragh MACCANN
James MCCLORY
Volker Schellenberger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amunix Pharmaceuticals Inc
Original Assignee
Amunix Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amunix Pharmaceuticals Inc filed Critical Amunix Pharmaceuticals Inc
Publication of AU2020308868A1 publication Critical patent/AU2020308868A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4204—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4205—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/49—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/50—Colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2020308868A 2019-06-26 2020-06-25 CD3 antigen binding fragments and compositions comprising same Pending AU2020308868A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962866746P 2019-06-26 2019-06-26
US62/866,746 2019-06-26
US202063041059P 2020-06-18 2020-06-18
US63/041,059 2020-06-18
PCT/US2020/039673 WO2020264200A1 (en) 2019-06-26 2020-06-25 Cd3 antigen binding fragments and compositions comprising same

Publications (1)

Publication Number Publication Date
AU2020308868A1 true AU2020308868A1 (en) 2022-01-20

Family

ID=74059962

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020308868A Pending AU2020308868A1 (en) 2019-06-26 2020-06-25 CD3 antigen binding fragments and compositions comprising same

Country Status (18)

Country Link
US (2) US20230121775A1 (cg-RX-API-DMAC7.html)
EP (1) EP3990497A4 (cg-RX-API-DMAC7.html)
JP (2) JP7651481B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220038068A (cg-RX-API-DMAC7.html)
CN (1) CN115175933A (cg-RX-API-DMAC7.html)
AU (1) AU2020308868A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021026089A2 (cg-RX-API-DMAC7.html)
CA (1) CA3143519A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021003448A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022000406A2 (cg-RX-API-DMAC7.html)
CR (1) CR20210628A (cg-RX-API-DMAC7.html)
DO (1) DOP2021000264A (cg-RX-API-DMAC7.html)
EC (1) ECSP22005986A (cg-RX-API-DMAC7.html)
IL (1) IL289102A (cg-RX-API-DMAC7.html)
MX (1) MX2021015880A (cg-RX-API-DMAC7.html)
PE (1) PE20220600A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021500051A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020264200A1 (cg-RX-API-DMAC7.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
KR20260039804A (ko) * 2017-12-21 2026-03-20 아뮤닉스 파마슈티컬스, 인크. 유리 세그먼트 및 이것을 포함하는 결합 조성물
KR20210124308A (ko) 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도
WO2020264200A1 (en) * 2019-06-26 2020-12-30 Amunix Pharmceuticals, Inc. Cd3 antigen binding fragments and compositions comprising same
MX2022014786A (es) 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.
PH12022553407A1 (en) * 2020-06-25 2024-04-22 Amunix Pharmaceuticals Inc Her-2 targeted bispecific compositions and methods for making and using the same
AU2021326469C1 (en) 2020-08-11 2026-04-30 Janux Therapeutics, Inc. Cleavable linker compositions and methods
EP4058474B1 (en) * 2020-08-20 2024-05-08 A2 Biotherapeutics, Inc. Compositions and methods for treating egfr positive cancers
EP4259193A4 (en) 2020-12-09 2025-01-15 Janux Therapeutics, Inc. Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens
WO2022170619A1 (en) * 2021-02-11 2022-08-18 Adagene Pte. Ltd. Anti-cd3 antibodies and methods of use thereof
CN117616137A (zh) * 2021-05-11 2024-02-27 佳努克斯治疗公司 靶向egfr和cd3的抗体及其用途
AR125758A1 (es) 2021-05-12 2023-08-09 Janux Therapeutics Inc Composiciones y métodos relacionados con anticuerpos activados por tumores dirigidos a egfr y antígenos de células efectoras
EP4433096A1 (en) * 2021-11-19 2024-09-25 Ardeagen Corporation Gpc3 binding agents, conjugates thereof and methods of using the same
WO2023192973A1 (en) * 2022-04-01 2023-10-05 Cytomx Therapeutics, Inc. Activatable multispecific molecules and methods of use thereof
CN116063498A (zh) * 2022-04-27 2023-05-05 博际生物医药科技(杭州)有限公司 单域抗Nectin-4抗体
CN116724057A (zh) * 2022-11-28 2023-09-08 浙江时迈药业有限公司 蛋白酶可切割的重组双特异性抗体和组合物及其用途
JP7855148B2 (ja) 2023-02-10 2026-05-07 アムニクス ファーマシューティカルズ, インコーポレイテッド 前立腺特異的膜抗原(psma)を標的とする組成物、並びにそれを作製及び使用するための方法
US20240400696A1 (en) 2023-04-17 2024-12-05 Amunix Pharmaceuticals, Inc. Compositions targeting epidermal growth factor receptor and methods for making and using the same
WO2024220870A1 (en) * 2023-04-19 2024-10-24 The University Of Chicago Antibody-targeted enzymatic chemoprotection
WO2024218715A1 (en) 2023-04-19 2024-10-24 Btl Healthcare Technologies A.S. Culture media based on protein hydrolysate and a process for preparing thereof
US12668774B2 (en) 2023-10-12 2026-06-30 Btl Healthcare Technologies A.S. Product, system and method of cell cultivation
KR20260114559A (ko) 2023-12-08 2026-07-22 아뮤닉스 파마슈티컬스, 인크. 프로테아제 활성화가능 사이토카인 및 이의 제조 및 사용 방법
CN120230203A (zh) * 2023-12-28 2025-07-01 四川思柏沃生物技术有限公司 抗cd3抗体及其用途
WO2025220804A1 (ko) * 2024-04-18 2025-10-23 주식회사 큐로셀 Cd5에 대한 신규 항체 및 이의 용도
WO2026024863A2 (en) 2024-07-24 2026-01-29 Amunix Pharmaceuticals, Inc. Compositions targeting prostate-specific membrane antigen (psma) in combination with androgen receptor antagonists
WO2026136923A1 (en) * 2024-12-20 2026-06-25 Vir Biotechnology, Inc. Therapeutic uses of her-2 targeted bispecific polypeptides

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4753894A (en) 1984-02-08 1988-06-28 Cetus Corporation Monoclonal anti-human breast cancer antibodies
US4943533A (en) 1984-03-01 1990-07-24 The Regents Of The University Of California Hybrid cell lines that produce monoclonal antibodies to epidermal growth factor receptor
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
US5534617A (en) 1988-10-28 1996-07-09 Genentech, Inc. Human growth hormone variants having greater affinity for human growth hormone receptor at site 1
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5412087A (en) 1992-04-24 1995-05-02 Affymax Technologies N.V. Spatially-addressable immobilization of oligonucleotides and other biological polymers on surfaces
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
CA2222231A1 (en) 1995-06-07 1996-12-19 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth of tumors
US5695937A (en) 1995-09-12 1997-12-09 The Johns Hopkins University School Of Medicine Method for serial analysis of gene expression
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
KR100945108B1 (ko) 2001-06-13 2010-03-02 젠맵 에이/에스 표피 성장 인자 수용체 (egfr)에 대한 인간모노클로날 항체
HUE035898T2 (en) 2002-12-16 2018-05-28 Genentech Inc Immunoglobulin variants and their applications
US8236308B2 (en) * 2005-10-11 2012-08-07 Micromet Ag Composition comprising cross-species-specific antibodies and uses thereof
EP2193149A1 (en) 2007-10-02 2010-06-09 Merck Patent GmbH Crystalline egfr - matuzumab complex and matuzumab mimetics obtained thereof
US8680050B2 (en) 2009-02-03 2014-03-25 Amunix Operating Inc. Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
US8703717B2 (en) 2009-02-03 2014-04-22 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
DK3178835T3 (da) 2009-02-03 2019-06-24 Amunix Pharmaceuticals Inc Forlængede rekombinante polypeptider og sammensætninger omfattende samme
PE20121539A1 (es) 2009-06-08 2012-12-06 Amunix Operating Inc Polipeptidos de la hormona de crecimiento y metodos de preparacion
WO2010144508A1 (en) 2009-06-08 2010-12-16 Amunix Operating Inc. Glucose-regulating polypeptides and methods of making and using same
CA2771999A1 (en) 2009-08-24 2011-03-10 Amunix Operating Inc. Coagulation factor vii compositions and methods of making and using same
WO2011028344A2 (en) 2009-08-25 2011-03-10 Amunix Operating Inc. Interleukin-1 receptor antagonist compositions and methods of making and using same
JP6400470B2 (ja) * 2011-05-16 2018-10-03 ジェネロン(シャンハイ)コーポレイション リミテッド 多重特異性Fab融合タンパク質および使用法
ES2770501T3 (es) 2012-07-11 2020-07-01 Bioverativ Therapeutics Inc Complejo del factor VIII con XTEN y proteína del factor de Von Willebrand y sus usos
US10548953B2 (en) 2013-08-14 2020-02-04 Bioverativ Therapeutics Inc. Factor VIII-XTEN fusions and uses thereof
US20160326249A1 (en) * 2014-01-15 2016-11-10 Zymeworks Inc. Bi-specific cd3 and cd19 antigen-binding constructs
CA2955947A1 (en) * 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
IL319047A (en) * 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
MY195059A (en) * 2015-09-23 2023-01-05 Regeneron Pharma Optimized Anti-CD3 Bispecific Antibodies and Uses Thereof
KR20260039804A (ko) * 2017-12-21 2026-03-20 아뮤닉스 파마슈티컬스, 인크. 유리 세그먼트 및 이것을 포함하는 결합 조성물
WO2020264200A1 (en) * 2019-06-26 2020-12-30 Amunix Pharmceuticals, Inc. Cd3 antigen binding fragments and compositions comprising same
EP4058466A1 (en) * 2019-11-13 2022-09-21 Amunix Pharmaceuticals, Inc. Barcoded xten polypeptides and compositions thereof, and methods for making and using the same

Also Published As

Publication number Publication date
US20210054077A1 (en) 2021-02-25
JP2022537824A (ja) 2022-08-30
BR112021026089A2 (pt) 2022-03-22
JP7651481B2 (ja) 2025-03-26
EP3990497A4 (en) 2023-07-19
JP2025106277A (ja) 2025-07-15
CL2021003448A1 (es) 2022-09-09
DOP2021000264A (es) 2022-05-15
US20230121775A1 (en) 2023-04-20
CN115175933A (zh) 2022-10-11
CR20210628A (es) 2022-03-22
MX2021015880A (es) 2022-03-22
CO2022000406A2 (es) 2022-05-31
KR20220038068A (ko) 2022-03-25
IL289102A (en) 2022-02-01
PE20220600A1 (es) 2022-04-25
PH12021500051A1 (en) 2023-01-23
ECSP22005986A (es) 2022-04-29
EP3990497A1 (en) 2022-05-04
CA3143519A1 (en) 2020-12-30
WO2020264200A1 (en) 2020-12-30

Similar Documents

Publication Publication Date Title
US20230121775A1 (en) Cd3 antigen binding fragments and compositions comprising same
US20250163153A1 (en) Release segments and binding compositions comprising same
AU2026200378C1 (en) Chimeric polypeptide assembly and methods of making and using the same
US20230312729A1 (en) Egfr antigen binding fragments and compositions comprising same
WO2020131697A2 (en) Twin immune cell engager
BR122026001258A2 (pt) Método de fabricação de um polipeptídeo recombinante e uso de um polipeptídeo recombinante ou de uma composição que compreende o mesmo
BR112018004045B1 (pt) Construto de conjunto de polipeptídeo quimérico e seu uso
BR122025010451A2 (pt) Conjunto de polipeptídeo quimérico, seu uso, composição farmacêutica e ácido nucleico isolado